# Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer

> **NCT00001269** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 100 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** IL-3

## Key facts

- **NCT ID:** NCT00001269
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-05
- **Primary completion:** —
- **Final completion:** 2001-02
- **Target enrollment:** 100 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001269, "Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00001269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*